Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: LOVAZA Clear all
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 22, 2026, 3:05 PM EDT
No Longer Available No phase listed Expanded access

Pulmonary Vein Isolation Outcomes With Fish Oils

NCT00841451
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Lovaza (Fish Oils)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
U.S. locations
3
States / cities
Ridgewood, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 22, 2026, 3:05 PM EDT
Withdrawn Phase 4 Interventional

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

NCT01180764
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza (Omega-3 acid ethyl esters), Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 22, 2026, 3:05 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL

NCT04386577
View directory record Official record
Conditions
Aging
Interventions
Vitamin D3 (cholecalciferol), fish oil
Dietary Supplement · Drug
Lead sponsor
Augusta University
Other
Eligibility
50 Years and older
Enrollment
1,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

NCT00903409
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Simvastatin + Lovaza® (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
40
States / cities
Mobile, Alabama • Encinitas, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Phase 4 Interventional Results available

Lovaza® and Microvascular Function in Type 2 Diabetes

NCT00931879
View directory record Official record
Conditions
Hypertriglyceridemia, Diabetic Neuropathy
Interventions
omega-3-ethyl esters, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

NCT01431690
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
warfarin, omefas, omega-3-acid ethyl esters
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 22, 2026, 3:05 PM EDT
Withdrawn Phase 2 Interventional

Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury

NCT02990091
View directory record Official record
Conditions
TBI
Interventions
Omega 3 fatty acid, Safflower seed oil
Drug · Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Omega-3 Fatty Acids and Muscle Protein Synthesis

NCT00794079
View directory record Official record
Conditions
Healthy
Interventions
omega-3 fatty acids, corn oil
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 22, 2026, 3:05 PM EDT
Terminated Phase 4 Interventional

Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD

NCT01778647
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Stimulants plus Lovaza, Stimulants plus placebo
Dietary Supplement · Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
6 Years to 15 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pro-Resolving Mediators in Acute Inflammation in Humans

NCT04308889
View directory record Official record
Conditions
Inflammation; Skin, Resolution, Blister
Interventions
Lovaza, Cantharone, Phlebotomy
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture (VITAL)

NCT01747447
View directory record Official record
Conditions
Bone Density, Body Composition, Bone Health
Interventions
Vitamin D3 placebo, Fish oil placebo, omega-3 fatty acids (fish oil), Vitamin D3
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
771 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 22, 2026, 3:05 PM EDT
Terminated Not applicable Interventional Results available

Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients

NCT01002118
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Omega-3 Acid Ethyl Esters, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Not applicable Interventional

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids

NCT01624727
View directory record Official record
Conditions
Coronary Heart Disease, Metabolic Syndrome
Interventions
Omega 3 acid ethyl esters
Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Milton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Early Phase 1 Interventional Results available

COGNUTRIN in Breast Cancer Survivors

NCT01823991
View directory record Official record
Conditions
Breast Cancer
Interventions
VitaBlue™, Placebo, Lovaza®
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 22, 2026, 3:05 PM EDT
Not listed Phase 2 Interventional

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

NCT01202812
View directory record Official record
Conditions
Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions
Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 19 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2010 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

NCT01047683
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 22, 2026, 3:05 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries

NCT00935766
View directory record Official record
Conditions
Metabolic Diseases, Endocrine System Diseases, Heart Disease, Vascular Diseases, Diabetes, Cardiovascular Disease, Glucose Metabolism Disorders, Hypertension
Interventions
Omega-3, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention

NCT01282580
View directory record Official record
Conditions
Breast Cancer
Interventions
Lovaza-Omega 3 fatty acid capsules, Dietary fish (canned salmon, albacore)
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 22, 2026, 3:05 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

NCT03598309
View directory record Official record
Conditions
Lung Diseases, Lung Cancer, Protection Against
Interventions
Curcumin C3 complex®, Lovaza®, Placebo
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
55 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 3:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Fish Oil Study for High Triglyceride Levels in Children

NCT00915902
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Babu Balagopal
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Wilmington, Delaware • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 22, 2026, 3:05 PM EDT